Olaparib (Lynparza) plus bevacizumab (Avastin) is available through the Cancer Drugs Fund as a possible maintenance treatment for advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer in adults when:
- there has been a complete or partial response after first-line platinum-based chemotherapy plus bevacizumab, and
- the cancer is associated with homologous recombination deficiency.
More evidence on olaparib with bevacizumab is being collected to address uncertainties about the treatment. After this, NICE will decide whether or not to recommend it for use on the NHS and update the guidance. It will be available through the Cancer Drugs Fund until then.
If you are not eligible for olaparib with bevacizumab but are already having it, you should be able to continue until you and your doctor decide when best to stop.
Is this treatment right for me?
Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. Read more about making decisions about your care.
Questions to think about
- How well does it work compared with other treatments?
- What are the risks or side effects? How likely are they?
- How will the treatment affect my day-to-day life?
- What happens if the treatment does not work?
- What happens if I do not want to have treatment? Are there other treatments available?
Information and support
The NHS website may be a good place to find out more.
These organisations can give you advice and support:
- Ovarian Cancer Action, 0207 380 1730
- Ovacome, 0207 380 1730
- Target Ovarian Cancer, 0207 923 5475
- Cancer Research UK, 0808 800 4040
- Macmillan Cancer Support, 0808 808 0000
You can also get support from your local Healthwatch.
NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.
This page was last updated: